Latest From NovaScan LLC
The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.
The rates of reoperation after breast conservation therapy vary between 25 and 49%, due to the presence of tumor cells remaining in the surrounding tissue after the tumor is removed. NovaScan hopes to reduce the need for these reoperations. Its FastPath residual cancer probe is designed to identify normal, benign and malignant tissue types remaining inside the surgical cavity and in excised tissue in real time during surgery.
Mammography is a mature and successful breast cancer diagnostic technology, but it has many drawbacks, including high false-negative and false-positive rates, the use of ionizing radiation, and ineffectiveness in dense or scarred breast tissue. Emerging companies aim to improve on this gold standard as well as streamline radiological workflow and predict disease aggressiveness and recurrence. START-UP profiles four such companies in this issue: Delphinus Medical Technologies, Ibris, NovaScan and Real Time Tomography.
This Month's Profile Group: Breast Cancer Diagnostics: Start-Ups Look To Fill Gaps In The Patient Care Continuum, features profiles of Delphinus Medical Technologies, Ibris, NovaScan and Real Time Tomography. Plus these Start-Ups Across Health Care: NewGen Therapeutics, Ozics, PlantForm and PsiOxus.
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- NovaScan Systems LLC
- North America
- Parent & Subsidiaries
- NovaScan LLC
- Senior Management
- William Gregory, PhD, CSO
- Contact Info
Phone: (414) 839-3279
Aurora Sinai Med. Ctr., 950 N. 12th St.
Milwaukee, WI 53233
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.